Gabapentin Tablet
Product Images NDC 72789-217

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 72789-217). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789217 Label (72789217)

Packaging label for Gabapentin USP 800 mg oral tablets from PD-Rx Pharmaceuticals, Inc. The label shows the product contains 60 tablets with the NDC 72789-217-60. Additional details include lot number K21D11 and expiration date 07/2023, along with warnings about drowsiness, avoiding alcohol, and not taking antacids simultaneously.*

FDA Label Image

Figure 1 (Image 01)

A line graph depicting mean pain scores over an eight-week period comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks, including a 4-week dose titration period followed by a 4-week fixed dose period, and the y-axis shows mean pain scores from 0 to 10. Gabapentin shows a greater decrease in pain score compared to placebo over time.*

FDA Label Image

Figure 2 (Image 02)

Line graph showing mean pain scores over 7 weeks comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period. Pain scores on the y-axis decrease over time for both Gabapentin groups compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) with two dosages of gabapentin (GBP) in two studies. Study 1 shows 12% response for placebo and 29% for GBP 3600 mg. Study 2 shows 14% response for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Image-04 (Image 04)

An illustration showing the formula for calculating creatinine clearance (CLCr) involving age, weight, serum creatinine, and a correction factor for female patients. This diagram is related to pharmacokinetic calculations and dosing considerations.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure diagram of Gabapentin showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxylic acid group (CH2CO2H).*

FDA Label Image

Image-09 (Image 09)

A scatter plot chart showing percent difference on the y-axis and daily dose in milligrams on the x-axis, comparing results from three studies labeled Study a, Study b, and Study c. The chart plots data points at doses of 600, 900, 1200, and 1800 mg, with Study a, b, and c represented by different square markers in black, gray, and white respectively.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.